EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

PAI-1, hematopoietic stem cell, and chronic myeloid leukemia

Naoto Takahashi, Hideo Harigae

Biomedical Journal · 2026-02 · 49 (1) · 100854

DOI: 10.1016/j.bj.2025.100854 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomedical Journal, 2026-02. Verfasst von Naoto Takahashi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan. Electronic address: naotot@doc.med…. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematopoietic Stem Cells, Plasminogen Activator Inhibitor 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The new treatment goal for chronic myeloid leukemia (CML) is treatment-free remission, which requires the achievement and maintenance of a deep molecular response (DMR) using a tyrosine kinase inhibitor (TKI). However, only a limited number of patients achieve or maintain DMR. TM5614, a PAI1 inhibitor, can bring quiescent hematopoietic stem cells from the bone marrow niche into the cell cycle. Thus, the combination of TM5614 and TKI may eradicate CML cells. Currently, a phase III clinical trial is confirming the efficacy of TM5614 and TKI combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveHematopoietic Stem CellsPlasminogen Activator Inhibitor 1HumansProtein Kinase Inhibitors

Stichwörter der Autor:innen

Chronic myeloid leukemiaDeep molecular responseHematopoietic stem cellsTreatment-free remissionTyrosine kinase inhibitor

Substanzen

Plasminogen Activator Inhibitor 1Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan. Electronic address: naotot@doc.med.akita-u.ac.jp.
  • Department of Hematology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Takahashi, N., & Harigae, H. (2026). PAI-1, hematopoietic stem cell, and chronic myeloid leukemia. Biomedical Journal, 49(1), 100854. https://doi.org/10.1016/j.bj.2025.100854

Vancouver

Takahashi N, Harigae H. PAI-1, hematopoietic stem cell, and chronic myeloid leukemia. Biomedical Journal. 2026;49(1):100854. doi:10.1016/j.bj.2025.100854

BibTeX
@article{Takahashi2026,
  author = {Takahashi, Naoto and Harigae, Hideo},
  title = {PAI-1, hematopoietic stem cell, and chronic myeloid leukemia},
  journal = {Biomedical Journal},
  year = {2026},
  volume = {49},
  number = {1},
  pages = {100854},
  doi = {10.1016/j.bj.2025.100854}
}
Kostenlos starten →